Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 9/20 | 1.00 |
| ▸ | MAOA known ✓ | P21397 | 7/20 | 1.00 |
| ▸ | KDM1A | O60341 | 14/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.95 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.95 |
| ▸ | HTR1A | P08908 | 1/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL4380284 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL56350 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL145687 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL56352 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL6388781 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL7759844 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL13785162 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL3406205 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL40651 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL1649712 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 806 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118147053-A | Culture system, kit and method for inducing mesenchymal stem cells | 成都赛济元生物医药有限公司 | 2024-06-07 | — | — | CN | claimed |
| US-11788145-B2 | Epigeneiic silencing of NMT2 | PACYLEX PHARMACEUTICALS INC. (CA) | 2023-10-17 | — | — | US | claimed |
| EP-3325662-B1 | EPIGENETIC SILENCING OF NMT2 | PACYLEX PHARMACEUTICALS INC (CA) | 2023-08-30 | — | — | EP | claimed |
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| EP-2841566-B1 | DERIVATION OF NEURAL STEM CELLS AND DOPAMINERGIC NEURONS FROM HUMAN PLURIPOTENT STEM CELLS | INT STEM CELL CORPORATION (US) | 2019-03-13 | — | — | EP | claimed |
| US-20190010461-A1 | HUMAN PLURIPOTENT STEM CELL-BASED SCREENING FOR SMOOTH MUSCLE CELL DIFFERENTIATION AND DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-10 | — | — | US | claimed |
| US-20180371423-A1 | NON-VIRAL IPSCS INDUCING METHOD, COMPOSITIONS, KITS AND IPSCS | Guangzhou Biocare Biotechnology Co., Ltd (CN) | 2018-12-27 | — | — | US | claimed |
| US-20180208990-A1 | EPIGENETIC SILENCING OF NMT2 | PACYLEX PHARMACEUTICALS INC. (CA) | 2018-07-26 | — | — | US | claimed |
| US-20180185478-A1 | TREATMENT FOR MYOPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-07-05 | — | — | US | claimed |
| EP-3325662-A1 | EPIGENETIC SILENCING OF NMT2 | Pacylex Pharmaceuticals Inc. (CA) | 2018-05-30 | — | — | EP | claimed |
| EP-2841566-A1 | DERIVATION OF NEURAL STEM CELLS AND DOPAMINERGIC NEURONS FROM HUMAN PLURIPOTENT STEM CELLS | International Stem Cell Corporation (US) | 2015-03-04 | — | — | EP | claimed |
| CN-104379732-A | Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells | INT STEM CELL CORP | 2015-02-25 | — | — | CN | claimed |
| WO-2013163228-A1 | DERIVATION OF NEURAL STEM CELLS AND DOPAMINERGIC NEURONS FROM HUMAN PLURIPOTENT STEM CELLS | INTERNATIONAL STEM CELL CORPORATION (US) | 2013-10-31 | — | — | WO | claimed |
| EP-2572192-A2 | A GENERAL MASS SPECTROMETRY ASSAY USING CONTINUOUSLY ELUTING CO-FRACTIONATING REPORTERS OF MASS SPECTROMETRY DETECTION EFFICIENCY | The UAB Research Foundation (US) | 2013-03-27 | — | — | EP | claimed |
| WO-2011146521-A2 | A GENERAL MASS SPECTROMETRY ASSAY USING CONTINUOUSLY ELUTING CO-FRACTIONATING REPORTERS OF MASS SPECTROMETRY DETECTION EFFICIENCY | THE UAB RESEARCH FOUNDATION (US) | 2011-11-24 | — | — | WO | claimed |
| US-8003080-B2 | Heating a coating, which includes an amine drug salt on a substrate to a temperature sufficient to volatilize the amine drug from the coating by heating, forming an amine drug vapor, drawing air, condensing vapor to form aerosol particles | ALEXZA PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | claimed |
| US-7109377-B2 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-19 | — | — | US | claimed |
| US-20060171945-A1 | Ip receptor antagonists for the treatment of pathological uterine conditions | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, THE (GB) | 2006-08-03 | — | — | US | claimed |
| US-20030082830-A1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-01 | — | — | US | claimed |
| US-6448443-B1 | GENERATED FROM DIVERSIFIABLE SCAFFOLDS SYNTHESIZED FROM THE PYRIDINE-BASED TEMPLATE ISONICOTINAMIDE; ALSO PROVIDES A NOVEL ORTHO-NITROBENZYL PHOTOLINKER; SYNTHESIZED FROM A SHIKIMIC ACID BASED EPOXYOL TEMPLATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-09-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208990-A1 | EPIGENETIC SILENCING OF NMT2 | NMT2, NNMT, NMT1 | MAOB 1825/4885MAOA 2403/4885KDM1A 66/4885 |
| US-20190010461-A1 | HUMAN PLURIPOTENT STEM CELL-BASED SCREENING FOR SMOOTH MUSCLE CELL DIFFERENTIATION AND DISEASE | MYH10, MYH14, MYH2 | MAOB 3258/4885MAOA 3220/4885KDM1A 495/4885 |
| US-11788145-B2 | Epigeneiic silencing of NMT2 | NNMT, NMT2, NMT1 | MAOB 1662/4885MAOA 2633/4885KDM1A 103/4885 |
| US-20030082830-A1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | TKFC, NISCH, PTGIS | MAOB 183/4885MAOA 290/4885KDM1A 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.